GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.

摘要: Type 2 diabetes (T2D) and associated obesity have reached epidemic proportions, there is an increasing need for orally effective agents that regulate glucose homeostasis with a concurrent reduction in body weight. GPR119, class-A (rhodopsin-like) G protein-coupled receptor, expressed primarily the human pancreas gastrointestinal tract, has attracted considerable interest as T2D drug target last three to five years. The activation of GPR119 increases intracellular accumulation cAMP, leading enhanced glucose-dependent insulin secretion increased levels incretin hormones GLP-1 (glucagon-like peptide 1) GIP (glucose-dependent insulinotropic peptide). In rodent models, available GPR119-specific agonists been shown attenuate blood simultaneous weight loss. This review summarizes research identification potential related metabolic disorders. addition, overview recent progress made discovery active provided.